Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156798 | 0.82 | HSP90AA1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30482995 | 0.78 | SIRT6 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28347446 | 0.77 | HSP90AA1 (0.40) | TSHRADORA3MC4RADRA1AMC3R | |
| SCHEMBL9755023 | 0.75 | KDM4E (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10818297 | 0.74 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16738333 | 0.74 | GPR84 (0.40) | ADORA3KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL3614621 | 0.73 | KDM4E (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3924183 | 0.73 | KDM4E (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL368929 | 0.73 | KCNH2 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28762999 | 0.72 | HSP90AA1 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| EP-2468720-A1 | Process for producing arylsulfur pentafluorides | UBE Industries, Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7342019-B2 | 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| CN-1620438-A | 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | GABRP 157/4885GABRD 514/4885GABRA1 191/4885 |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | GABRP 388/4885GABRD 892/4885GABRA1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.